DOCSLIB.ORG

Update on Ionis Pharmaceuticals June 7, 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Update on Ionis Pharmaceuticals June 7, 2016 Update on Ionis Pharmaceuticals June 7, 2016 Due to recent announcements and ongoing price weakness in the stock of Ionis Pharmaceuticals, we wanted to provide you an update on our thinking relating to your investment in the company. Background: Buena Vista Investment Management began investing in Ionis Pharmaceuticals (previously known as Isis Pharmaceuticals) in 2004 based on our belief that their genetic research and unique approach to discovering new drugs through the use of Antisense Technology would eventually lead to a much higher stock price. Since that first investment 12 years ago we have seen many ups and downs in the stock price but through it all the company’s technology continues to improve and its balance sheet has never been better. As investors, we entered 2016 with the potential for a lot of good news. First, the company had three phase 3 trials coming to endpoints within 18 months. Second, the company’s new subsidiary, Akcea Therapeutics, which was created to focus on their lipid franchise, was now up and running. The company had an exceptionally strong balance sheet for a biotechnology company, with approximately $700 million in cash and marketable securities. And most importantly, the company now had 38 compounds in clinical trials, an unheard of number for a company of this size. Yet with all of these potential positive catalysts for the stock, we are now sitting at the same price level as we were in the beginning of 2014. The price of Ionis stock has dropped from a high of $77 per share in April of 2015 to the mid 20’s today. As investors, we now need to decide whether or not there is a problem with the company. We can then make the decision to retain or sell the investment. In some cases, we also have to determine if this price decline has given us an opportunity to add to existing positions or to initiate new positions. What we do know: 1. Investing in a biotechnology company requires patience and a long‐term time horizon and therefore, we expect larger than normal investment returns. Stocks in this area can be extremely volatile as we have seen with Ionis. 2. The company has extremely new and efficient technology. There are no other biotechnology companies, to our knowledge, the size of Ionis that have so many compounds in clinical trials. It is also the first new drug discovery platform in 40 years. All this make Ionis a company which is very unique and hard to value. 3. The company’s drug discovery platform has evolved and improved over the time we have been investors. The improvements in the company’s chemistry have caused the new medicines being tested to be more powerful and have fewer side effects. Potency has increased 10 fold between generation 2.0 and generation 2.5 medicines. And the company’s LICA technology has shown a 30 fold increase in potency during APO(a)‐L Rx trials. 4. The company has consistently said over the years that their drugs have no drug ‐ drug interactions. This is a very valuable and important point to us as investors in this company. Update on Ionis Pharmaceuticals (continued) So why then has the stock performed so poorly over the last year? 1. The stock was $22 per share in 2014 then it soared to $77 per share at the beginning of 2015. In our opinion this move was too far, too fast and some retracements of the price gains were both normal and healthy. 2. Biotechnology stocks in general have been weak since the end of 2015. The IShares NASDAQ biotechnology ETF was down 40% since peaking in 2015 due to pricing and political concerns. With Ionis being part of this sector, it will be subject to the same kind of volatility. 3. The most recent price decline in Ionis stock was due to an announcement that Glaxo had delayed a phase 3 trial for the Ionis drug TTR‐Rx. The trial was delayed because of decreased platelet levels in some patients. During the conference call the company also indicated that they had seen decreased platelets in a different clinical trial for its lipid drug, Volanesorsen. This caused a number of brokerage firms to raise questions about the company’s technology and the potential value of its platform. We have attached, as part of this document, some slides from the Ionis annual meeting, which took place June 3rd, and details what they know about the platelet issue. What decisions has Buena Vista made relating to your investment in Ionis Pharmaceuticals? 1. Company Management ‐ Over my 12 years as an investor in Ionis we have had 4 meetings with Dr. Stanley Crooke, the founder of the company and/or Lynn Parshall the company’s current COO. Everything that they have told us over the years has come to be realized but it has taken time and was not always without some bumps. Given that we are investing in a biotechnology company it is important that we have confidence in the management team. Based on their handling of current and past events we maintain a high regard for the management team at Ionis. 2. The Antisense Technology Platform ‐ While we are not chemists, biologists or scientists, we have come to understand that the antisense platform is efficient and cost effective way to develop new medicines. The current platelet problem notwithstanding, the technology is evolving and improving. Antisense technology is not the only way to develop medicines but is one way that may improve the lives of people affected by serious diseases. 3. Wall Street –After the recent announcement of the Ionis platelet problem, two major Wall Street firms cut their price targets in half. One firm moved their target from $49 to $20 and the other from $53 to $25. After spending some time listening to company management it would be our position that these changes in price targets moved the stock more than was reasonable from an investment perspective. 4. Your investment in Ionis Pharmaceuticals ‐ After listening to the company’s review of the platelet problem during last Friday’s annual meeting, talking with a member of the management team and doing our own research, it would be our opinion that that Ionis stock should be retained. The recent decline in price offers an opportunity to purchase shares at a reasonable valuation and we will be purchasing shares in accounts, where appropriate. Please contact any member of the Buena Vista management team with questions. Respectfully submitted John Moffat, Partner Buena Vista Investment Management LLC Issues Regarding Platelet Declines Very few cases of serious platelet declines in Phase 3 studies IONIS-TTRRx in NEURO-TTR study Volanesorsen in APPROACH FCS study Misperception that serious platelet declines may have broader implications 7 What We Know About Platelet Declines Platelet reductions are a frequently observed sporadic side effect of many drugs Most are “idiosyncratic” meaning mechanism unknown Platelet reductions are easily monitored and managed Many potential contributors to platelet reductions Drug/disease-specific interaction Concomitant medications Infections 8 Partial List of Drugs/Classes Known to Cause Thrombocytopenia Others Over-the-Counter Antibiotic Chemotherapy Arrhythmia Acetaminophen Aminosalicylic acid Interferon-a Amiodarone Danazol (fibrotic breast disease) Aspirin Amphotericin B lrinotecan Digitoxin Ibuprofen Oxaliplatin Digoxin Diatrizoate meglumine- Naproxen Ampicillin Quinidine diatrizoate sodium Ceftriaxone (imaging agent) Neuro/ Cholesterol Co-trimoxazole Antidepressant Anti- Simvastatin Ethambutol Carbamazepine inflammatory Methicillin Aminoglutethimide Desipramine Diclofenac Hypertension Nalidixic acid Diazepam Meclofenamate Chlorothiazide Novobiocin Haloperidol Sulfasalazine Methyldopa Penicillin Mirtazapine Phenytoin Piperacillin Anti-parasitic Blood thinner Valproic acid Rifampicin Levamisole Abciximab Quinidine Eptifibatide Rifampin Quinine Sulfisoxazole Heartburn Heparin Stibophen Cimetidine Tirofiban Trimethoprim Suramin Sulfamethoxazole Ranitidine Vancomycin Beta-blocker Alprenolol Oxprenolol 9 Arnold, D.M. et al. (2013) Transfus Med Rev. 27:137-145 Partial List of Drugs/Classes Known to Cause Thrombocytopenia Others Over-the-Counter Antibiotic Chemotherapy Arrhythmia Acetaminophen Aminosalicylic acid Interferon-a Amiodarone Danazol (fibrotic breast disease) Aspirin Amphotericin B lrinotecan Digitoxin Ibuprofen Oxaliplatin Digoxin Diatrizoate meglumine- Naproxen Ampicillin Quinidine diatrizoate sodium Ceftriaxone (imaging agent) Neuro/ Cholesterol Co-trimoxazole Antidepressant Anti- Simvastatin Ethambutol Carbamazepine inflammatory Methicillin Aminoglutethimide Desipramine Diclofenac Hypertension Nalidixic acid Diazepam Meclofenamate Chlorothiazide Novobiocin Haloperidol Sulfasalazine Methyldopa Penicillin Mirtazapine Phenytoin Piperacillin Anti-parasitic Blood thinner Valproic acid Rifampicin Levamisole Abciximab Quinidine Eptifibatide Rifampin Quinine Sulfisoxazole Heartburn Heparin Stibophen Cimetidine Tirofiban Trimethoprim Suramin Sulfamethoxazole Ranitidine Vancomycin Beta-blocker Alprenolol Oxprenolol 10 Arnold, D.M. et al. (2013) Transfus Med Rev. 27:137-145 Serious Declines in Platelets are Not a Class Effect Observed with Second Generation Antisense Drugs Not a class effect of 2’ methoxyethyl second generation antisense drugs Serious platelet declines in only two of more than 15 second generation drugs studied in the clinic (over 3,000 people treated in our integrated safety database) No evidence of cumulative dosing effect with second generation antisense drugs Patients treated responsive to dose pause and steroid treatment Platelet declines not due to these serious
Load more

Recommended publications
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste
    NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste (+)-A-TOCOPHEROL ACID SUCCINATE (+,-)-VERAPAMIL, HYDROCHLORIDE 1-AMINOANTHRAQUINONE 1-AMINO-1-CYCLOHEXANECARBOXYLIC ACID 1-BROMOOCTADECANE 1-CARBOXYNAPHTHALENE 1-DECENE 1-HYDROXYANTHRAQUINONE 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE HYDROCHLORIDE 1-NONENE 1-TETRADECENE 1-THIO-B-D-GLUCOSE 1-TRIDECENE 1-UNDECENE 2-ACETAMIDO-1-AZIDO-1,2-DIDEOXY-B-D-GLYCOPYRANOSE 2-ACETAMIDOACRYLIC ACID 2-AMINO-4-CHLOROBENZOTHIAZOLE 2-AMINO-2-(HYDROXY METHYL)-1,3-PROPONEDIOL 2-AMINOBENZOTHIAZOLE 2-AMINOIMIDAZOLE 2-AMINO-5-METHYLBENZENESULFONIC ACID 2-AMINOPURINE 2-ANILINOETHANOL 2-BUTENE-1,4-DIOL 2-CHLOROBENZYLALCOHOL 2-DEOXYCYTIDINE 5-MONOPHOSPHATE 2-DEOXY-D-GLUCOSE 2-DEOXY-D-RIBOSE 2'-DEOXYURIDINE 2'-DEOXYURIDINE 5'-MONOPHOSPHATE 2-HYDROETHYL ACETATE 2-HYDROXY-4-(METHYLTHIO)BUTYRIC ACID 2-METHYLFLUORENE 2-METHYL-2-THIOPSEUDOUREA SULFATE 2-MORPHOLINOETHANESULFONIC ACID 2-NAPHTHOIC ACID 2-OXYGLUTARIC ACID 2-PHENYLPROPIONIC ACID 2-PYRIDINEALDOXIME METHIODIDE 2-STEP CHEMISTRY STEP 1 PART D 2-STEP CHEMISTRY STEP 2 PART A 2-THIOLHISTIDINE 2-THIOPHENECARBOXYLIC ACID 2-THIOPHENECARBOXYLIC HYDRAZIDE 3-ACETYLINDOLE 3-AMINO-1,2,4-TRIAZINE 3-AMINO-L-TYROSINE DIHYDROCHLORIDE MONOHYDRATE 3-CARBETHOXY-2-PIPERIDONE 3-CHLOROCYCLOBUTANONE SOLUTION 3-CHLORO-2-NITROBENZOIC ACID 3-(DIETHYLAMINO)-7-[[P-(DIMETHYLAMINO)PHENYL]AZO]-5-PHENAZINIUM CHLORIDE 3-HYDROXYTROSINE 1 9/26/2005 NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste 3-HYDROXYTYRAMINE HYDROCHLORIDE 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • The International Pharmacopoeia
    The International Pharmacopoeia THIRD EDITION Pharmacopoea internationalis Editio tertia Volume 4 Tests, methods, and general requirements Quality specifications for pharmaceutical substances, excipients, and dosage forms World Health Organization Geneva 1994 WHO Library Cataloguing in Publication Data The International Pharmacopoeia.- 3rd ed. Contents: v. 4. Tests, methods, and general requirements 1. Drugs -analysis 2. Drugs -standards ISBN 92 4 154462 7 (NLM Classification: QV 25) The World Health Organization welcomes requests for permission to reproduce or translate its publica- tions, in part or in full. Applications and enquiries should be addressed to the Of£ice of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available. O World Health Organization, 1994 Publications of the World Health Organization enjoy copyright protection in accordance with the provi- sions of Protocol 2 of the Universal Copyright Convention. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distin- guished by initial capital letters.
    [Show full text]
  • Diatrizoate Sodium)
    PRESCRIBING INFORMATION HYPAQUE ORAL POWDER (Diatrizoate Sodium) Contrast Medium GE Healthcare Canada Inc. Date of Preparation: 2300 Meadowvale Blvd. March 20, 2006 Mississauga, ON L5N 5P9 Control # 104484 HYPAQUE ORAL (Diatrizoate Sodium) CONTRAST MEDIUM INDICATIONS: Radiography of gastrointestinal tract following oral or rectal administration. PRECAUTIONS: Not for parenteral injection. Do not use for myelography. It is advisable to correct any electrolyte disturbances before using solutions that are extremely hypertonic. Caution is advised in patients with severe renal or hepatic disease, known hypersensitivity to diatrizoic acid compounds or hyperthyroidism. Pregnancy: The safety of orally administered diatrizoate sodium solutions during pregnancy has not been established. Therefore, before administration of the drug to women of childbearing potential, the benefit to the patient should be carefully weighed against the possible risk to the fetus. In addition, most authorities consider elective contrast radiography of the abdomen contraindicated during pregnancy. Lactation: Diatrizoate sodium administered intravascularly has been found to be excreted in breast milk. Because small amounts may be absorbed from oral administration, caution should be exercised when diatrizoate sodium solutions are administered to a nursing woman. Children: Solutions of diatrizoate sodium employed clinically are hypertonic, which may lead to intraluminal movement of fluid and may lead to hypovolemia. In infants and young children (under 10 kg), the loss of plasma fluid may be sufficient to cause a shock-like state; therefore, low concentrations (achieved by further dilution) must be used. Diatrizoate sodium may be preferred over the diatrizoate meglumine/diatrizoate sodium combination, since the wetting agent (Tween 80) in the latter preparation may be injurious to the colonic mucosa.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Diatrizoate Meglumine and Diatrizoate Sodium
    PATIENT & CAREGIVER EDUCATION Diatrizoate Meglumine and Diatrizoate Sodium This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Gastrografin; MD-76 R [DSC]; MD-Gastroview [DSC] Brand Names: Canada Gastrografin Warning Injection: This drug must not be given into the spine. What is this drug used for? It is used before an x-ray or other test like it. What do I need to tell the doctor BEFORE my child takes this drug? All products: If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. If your child is dehydrated, has been eating poorly, or has used a laxative or Diatrizoate Meglumine and Diatrizoate Sodium 1/8 water pill before this drug. If your child has had a skin reaction to this drug or another drug like it in the past. If your child is taking metformin. Oral liquid: If your child has a health problem that connects the windpipe (trachea) to the swallowing tube (esophagus) called esophagotracheal fistula. This is not a list of all drugs or health problems that interact with this drug. Tell the doctor and pharmacist about all of your child’s drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe to give this drug with all of your child’s other drugs and health problems.
    [Show full text]
  • GASTROGRAFIN- Diatrizoate Meglumine and Diatrizoate Sodium Liquid Bracco Diagnostics Inc ------GASTROGRAFIN® Diatrizoate Meglumine and Diatrizoate Sodium Solution USP
    GASTROGRAFIN- diatrizoate meglumine and diatrizoate sodium liquid Bracco Diagnostics Inc ---------- GASTROGRAFIN® Diatrizoate Meglumine and Diatrizoate Sodium Solution USP DESCRIPTION Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is a palatable lemon-flavored water-soluble iodinated radiopaque contrast medium for oral or rectal administration only. Each mL contains 660 mg diatrizoate meglumine and 100 mg diatrizoate sodium; pH has been adjusted to 6.0 to 7.6 with sodium hydroxide. Each mL contains approximately 4.8 mg (0.21 mEq) sodium and 367 mg organically bound iodine. Inactive ingredients: edetate disodium, flavor, polysorbate 80, purified water, saccharin sodium, simethicone, and sodium citrate. Diatrizoate meglumine is designated chemically as 1-deoxy-1-(methylamino)-D-glucitol 3,5- diacetamido-2,4,6-triiodo-benzoate (salt); diatrizoate sodium is monosodium 3, 5-diacetamido-2,4,6- triiodobenzoate. Structural formulas: CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast with surrounding tissues. Diagnostic enteral radiopaque agents have few known pharmacological effects. Diatrizoate meglumine and diatrizoate sodium exert a mild laxative effect attributable to their high osmolarity. Diatrizoate meglumine and diatrizoate sodium are sparingly absorbed from the intact gastrointestinal tract, and therefore permit gastrointestinal opacification and delineation after oral or rectal administration. Oral administration is used for radiographic evaluation of the esophagus, stomach and proximal small intestine. Rectal administration is used for examination of the colon; however, visualization of the distal small bowel is generally unsatisfactory, since the hypertonicity of the medium causes intraluminal diffusion of water with subsequent dilution of the medium.
    [Show full text]
  • Structure and Properties of X-Ray Contrast Media
    STRUCTURE AND PROPERTIES OF X-RAY CONTRAST MEDIA Optimal use of CM in radiology requires a knowl- edge of the nature and relevant properties of the available substances. This chapter describes the properties of currently used and newly developed contrast-giving agents that infuence their behav- ior in the human body, their side effects, and their practical utility. The main X-ray contrast agents in use today are insoluble barium sulfate for the diagnostic evalu- ation of the GI tract and water-soluble CM for the radiological assessment of the different vascular systems, body cavities and organs. In addition, a water-soluble CM based on tri-iodobenzene is the alternative agent of choice for oral use when bari- um sulfate is contraindicated. Barium Sulfate Barium is used in the form of the insoluble sulfate for radiography of the GI tract. If perforation is suspected, however, only water-soluble, iodinated agents (Gastrografn, Ultravist-370) can be used since the body is virtually incapable of eliminating barium sulfate once it has entered the peritoneum. Barium sulfate is available either as a powder to be prepared directly before use or as a ready-to-use suspension. For double-contrast examinations (fll- ing of the lumen with gas, coating of the wall with barium sulfate), barium sulfate is either mixed with a carbon dioxide additive, or a gas-forming agent is taken in addition. © The Author(s) 2018 20 U. Speck, X-Ray Contrast Media, https://doi.org/10.1007/978-3-662-56465-3_3 Common to all barium preparations is concentra- tion of barium sulfate which may diluted according to the needs of the examination.
    [Show full text]
  • 118 Part 520—Oral Dosage Form New Animal Drugs
    § 516.1318 21 CFR Ch. I (4–1–12 Edition) associated with Flavobacterium 520.45a Albendazole suspension. columnare. 520.45b Albendazole paste. (iii) Limitations. Feed containing 520.48 Altrenogest. florfenicol shall not be fed to catfish 520.62 Aminopentamide hydrogen sulphate tablets. for more than 10 days. Following ad- 520.82 Aminopropazine fumarate oral dosage ministration, fish should be reevalu- forms. ated by a licensed veterinarian before 520.82a Aminopropazine fumarate tablets. initiating a further course of therapy. 520.82b Aminopropazine fumarate, neomy- A dose-related decrease in cin sulfate tablets. hematopoietic/lymphopoietic tissue 520.88 Amoxicillin oral dosage forms. may occur. The time required for 520.88a Amoxicillin trihydrate film-coated hematopoietic/lymphopoietic tissues to tablets. 520.88b Amoxicillin trihydrate for oral sus- regenerate was not evaluated. The ef- pension. fects of florfenicol on reproductive per- 520.88c Amoxicillin trihydrate oral suspen- formance have not been determined. sion. Feeds containing florfenicol must be 520.88d Amoxicillin trihydrate soluble pow- withdrawn 12 days prior to slaughter. der. Federal law limits this drug to use 520.88e Amoxicillin trihydrate boluses. under the professional supervision of a 520.88f Amoxicillin trihydrate tablets. licensed veterinarian. The expiration 520.88g Amoxicillin trihydrate and clavulanate potassium film-coated tab- date of veterinary feed directives lets. (VFDs) for florfenicol must not exceed 520.88h Amoxicillin trihydrate and 15 days from the date of prescribing. clavulanate potassium for oral suspen- VFDs for florfenicol shall not be re- sion. filled. See § 558.6 of this chapter for ad- 520.90 Ampicillin oral dosage forms. ditional requirements. 520.90a Ampicillin capsules.
    [Show full text]
  • Federal Register/Vol. 79, No. 97/Tuesday, May 20
    Federal Register / Vol. 79, No. 97 / Tuesday, May 20, 2014 / Rules and Regulations 28813 DEPARTMENT OF HEALTH AND animal drug applications (NADAs) and Medicine (HFV–100), Food and Drug HUMAN SERVICES 14 approved abbreviated new animal Administration, 7520 Standish Pl., drug applications (ANADAs) for oral Rockville, MD 20855, 240–276–8300, Food and Drug Administration dosage form new animal drug products [email protected]. from Pfizer, Inc., including its several 21 CFR Parts 510 and 520 subsidiaries and divisions, to Zoetis, SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 E. 42d St., New York, NY [Docket No. FDA–2014–N–0002] Inc. FDA is also amending the animal drug regulations to remove entries 10017, and its wholly owned Oral Dosage Form New Animal Drugs; describing conditions of use for new subsidiaries Alpharma, LLC; Fort Dodge Change of Sponsor animal drug products for which no Animal Health, Division of Wyeth; Fort NADA is approved, to make minor Dodge Animal Health, Division of AGENCY: Food and Drug Administration, corrections, and to reflect a current Wyeth Holdings Corp.; and its division, HHS. format. This is being done to increase Pharmacia & Upjohn Co., have informed ACTION: Final rule; technical the accuracy and readability of the FDA that they have transferred amendments. regulations. ownership of, and all rights and interest in, the 172 approved NADAs and 14 SUMMARY: The Food and Drug DATES: This rule is effective May 20, approved ANADAs in table 1 to Zoetis, Administration (FDA) is amending the 2014. Inc., 333 Portage St., Kalamazoo, MI animal drug regulations to reflect a FOR FURTHER INFORMATION CONTACT: change of sponsor for 172 approved new Steven D.
    [Show full text]